The p53 mutant HT29 colon carcinoma cell line has been extensively used to evaluate the potentiation of cytotoxic chemotherapy by Chk1 inhibitors [19-23] and was therefore used as the main test system for this study. The gene discussed is TP53; the disease is colon carcinoma.